OPPERMANN KATRIN
- former member of the university
Publications
38 Publications
2019
Journal Articles
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Auer, M; Hegen, H; Sellner, J; Oppermann, K; Bsteh, G; Di Pauli, F; Berger, T; Deisenhammer, F
BRAIN BEHAV. 2019; 9(7): e01332
Full papers/articles (Journal)
2017
Journal Articles
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Automated brain tissue and lesion segmentation in multiple sclerosis: A feasibility study in the state of Salzburg
Varosanec, M; Marschallinger, R; Karamyan, A; Sellner, J; Oppermann, K; Golaszewski, SM; Wipfler, P; McCoy, MR; Trinka, E
EUR J NEUROL. 2017; 24: 429-430.
Abstracts (Journal)
2016
Conference papers, proceedings, abstracts
Evidence of gender differences for initiation of therapy escalation in multiple sclerosis
Karamyan, A; Oppermann, K; Bacher, C; Otto, F; Pilz, G; Wipfler, P; Chroust, V; Sellner, J
MULT SCLER J. 2016; 22: 723-723.
Abstracts (Journal)
Prevalence and predictors of sexual dysfunction in multiple sclerosis: a cross-sectional study
Otto, F; Bacher, C; Chroust, V; Karamyan, A; Oppermann, K; Reisp, M; Pilz, G; Wipfler, P; Sellner, J
MULT SCLER J. 2016; 22: 727-727.
Abstracts (Journal)
2015
Journal Articles
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Full papers/articles (Journal)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Full papers/articles (Journal)
Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukencephalopathy with an excellent outcome
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Rispens, T; van der Kleij, D; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clinical and Experimental Neuroimmunology. 2015;
Case Reports
2014
Journal Articles
A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Full papers/articles (Journal)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Natalizumab and fingolimod differentially impact the alpha-4/beta-1 and alpha-L/beta-2 expression-related subset diversity of T-cells
Harrer, A; Oppermann, K; Wanek, J; Pilz, G; Wipfler, P; Sellner, J; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2014; 20: 333-333.
Abstracts (Journal)
2013
Journal Articles
Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J;
Neurology. 2013; 81(19): 1654-1658.
Full papers/articles (Journal)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Shift in the CD4+/CD8+ratio of cerebrospinal fluid T cells independent from free or cell-bound natalizumab
Harrer, A; Oppermann, K; Pizl, G; Wipfler, P; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 451-452.
Abstracts (Journal)
Flow-cytometry and the detection of natalizumab-neutralizing antibodies in multiple sclerosis
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Holl, B; Deisenhammer, F; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 500-501.
Abstracts (Journal)
2012
Journal Articles
Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.
Broussalis, E; Hutterer, M; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Haschke-Becher, E; Golaszewski, S; Schönauer, U; Weis, S; Killer-Oberpfalzer, M; Mc Coy, M; Trinka, E; Kraus, J;
Acta Neurol Scand. 2012; 126(3):e11-e16
Case Reports
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Full papers/articles (Journal)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Full papers/articles (Journal)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Reviews
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Full papers/articles (Journal)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Natalizumab Treatment Effects Sustained Decrease in Serum Levels of Fibronectin and Soluble Adhesion Molecules sVCAM-1 and sICAM-3
Kraus, J; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Journal)
Serum Levels of Soluble Adhesion Molecules Remain Stable during Short- and Long-Term Interferon-beta-1b Treatment
Kraus, J; Zaunrieth, R; Obregon-Castrillo, E; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Golaszewski, S; Hitzl, W; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Journal)
2011
Journal Articles
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Full papers/articles (Journal)
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Reviews
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Natalizumab binding to peripheral blood mononuclear cells analysed by flow cytometry can be used for monitoring treatment response in patients with multiple sclerosis
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 13-14.
Abstracts (Journal)
Anti-Inflammatory Effects of Copaxone on the Level of Adhesion Molecule Expression Patterns during Short- and Long-Term Treatment
Kraus, J; Oppermann, K; Harrer, A; Koczi, W; Duerr, EM; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E
NEUROLOGY. 2011; 76(9): A384-A384.
Abstracts (Journal)
Flow Cytometry of Natalizumab Binding to Immune Cells and Its Potential Use for Monitoring Disease Activity and Treatment Response in Patients with Multiple Sclerosis
Kraus, J; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2011; 76(9): A135-A136.
Abstracts (Journal)
Copaxone treatment shows anti-inflammatory effects on the level of adhesion molecule expression on peripheral blood mononuclear cells during short- and long-term therapy
Oppermann, K; Harrer, A; Koczi, W; Duerr, E; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 206-206.
Abstracts (Journal)
2010
Conference papers, proceedings, abstracts
Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections
Kraus, J; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Afazel, S; Haschke-Becher, E; Kunz, AB; Golaszewski, SM; Staffen, W; Ladurner, G
NEUROLOGY. 2010; 74(9): A416-A416.
Abstracts (Journal)
Short- and long-term decrease of soluble adhesion molecules (sICAM-1,-2,-3 and sVCAM-1) during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Harrer, A; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S220-S220.
Abstracts (Journal)
Expression levels of cell surface bound interferon-receptor remain stable during short- and long-term interferon beta-1b treatment
Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Duerr, EM; Koczi, W; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S219-S219.
Abstracts (Journal)
Accumulation of natalizumab at the VLA-4 receptor as a potential molecular basis of enhanced treatment efficacy and occurrence of opportunistic infections
Wipfler, P; Oppermann, K; Pilz, G; Harrer, A; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S8-S8.
Abstracts (Journal)
2009
Conference papers, proceedings, abstracts
Short-term decrease of soluble adhesion molecules during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Sulzer, C; Afazel, S; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Journal)
Therapeutic effect of natalizumab despite the presence of neutralising antibodies shown by cell surface bound alpha4-integrin expression
Pilz, G; Wipfler, P; Oppermann, K; Sulzer, C; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Journal)
Natalizumab Treatment Leads to Changes in Adhesion Molecule Expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G; Kraus, J
NEUROLOGY. 2009; 72(11): A37-A38.
Abstracts (Journal)
Long-term effect of natalizumab on cell surface bound adhesion molecules expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Huemer, M; Haschke-Becher, E; Staffen, W; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S195-S196.
Abstracts (Journal)